MT. KISCO, N.Y., March 15, 2012 (GLOBE NEWSWIRE) -- Immudyne, Inc. (Pink Sheets:IMMD) a leading industry provider of all-natural products for immune system support from yeast beta-glucan, today announced the Company will present the outcome of Its clinical phase I and pivotal cancer studies at the World Immune Regulator Meeting (WIRM) at the Congress Center in Davos, Switzerland on March 18, 2012.
